INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Non-Inferiority

NCT02832544 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

4565

Enrollment

OTHER

Sponsor class

Conditions

Rheumatic Heart Disease

Interventions

DRUG: Rivaroxaban (20 mg)
DRUG: Vitamin K antagonists (VKA)

Sponsor

Population Health Research Institute

Collaborators

[object Object]
[object Object]